Table 2 Clinical course
From: Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series
Pt | IL-6 Inhibitor | Hospital day IL-6i administered | Corticosteroids | CRP* | d-Dimer | ALC (%) | Treated for secondary infection (confirmed organism) | ICU admission | Mechanical ventilation | Discharged alive |
|---|---|---|---|---|---|---|---|---|---|---|
1 | Tocilizumab | 10 | Y | 21* | 1100 | 1.1 (38) | No | No | No | Yes |
2 | Tocilizumab | 3 | Y | 117* | 542 | 1.1 (25) | No | No | No | Yes |
3 | Tocilizumab | 9 | N | 94* | 4000 | 1.0 (14) | No | No | No | No |
4 | NR* | NR** | N | 15 | 1269 | 0.7 (10) | No | No | No | Yes |
5 | NR* | NR** | N | 308 | 1103 | 0.3 (6) | Yes (unknown) | Yes | Yes | No |
6 | Sarilumab | NR** | N | 68 | 226 | 1.7(32) | Yes (unknown) | Yes | Yes | Yes |
7 | NR* | NR** | N | 188 | 184 | 0.1 (4) | Yes (S. maltophilia) | Yes | Yes | No |
8 | NR* | NR** | N | 85 | NR | 0.7 (19) | No | No | No | Yes |
9 | NR* | NR** | N | 134 | 1115 | 0.6 (5) | No | No | No | Yes |
10 | NR* | NR** | N | 114 | 210 | 3.8 (34) | Yes (S. aureus) | Yes | Yes | Yes |
11 | NR* | NR** | N | 190 | 264 | 1.3 (14) | Yes (E. cloacae) | Yes | Yes | Yes |
12 | Sarilumab | NR** | N | 178 | 0 | 1.4 (13) | No | Yes | Yes | Yes |
13 | Sarilumab | NR** | N | 21 | 2 | 1.2 (11) | No | Yes | Yes | No |
14 | Sarilumab | NR** | N | 9 | 492 | 1.7 (29) | No | No | No | Yes |
15 | Sarilumab | NR** | N | 26 | 2 | 0.7 (8) | Yes (k.aaerogenes, S. epidermidis) | Yes | Yes | No |
16 | Sarilumab | NR** | N | 207 | 2 | 1.14 (11) | No | Yes | Yes | No |
17 | NR* | NR** | N | 187 | 315 | 0.2 (1) | Yes (unknown) | Yes | Yes | Yes |
18 | Tocilizumab | 4 | N | 7* | 1 | 1.0 (8) | Yes (V. Zoster) | Yes | Yes | No |